Monte Dirks, M.D. - Primary Investigator

Norfloxacin - Merck (1986)
“Safety and efficacy of norfloxacin vs. tobramycin in the treatment of external ocular infections.”

Metipranolol/Pilocarpine Combination – Bausch & Lomb 2809 (1992)
“The safety and efficacy of metipranolol 0.1%/pilocarpine 2% b.i.d., metipranolol 0.3%/pilocarpine 2% b.i.d., metipranolol 0.3% b.i.d., and pilocarpine 4% q.i.d. in patients with ocular hypertension or glaucoma.”

“The long-term safety and efficacy of Brimonidine Tartrate 0.2% in individuals with open-angle glaucoma or ocular hypertension.”

“A comparison in the long-term effect on stability of intraocular pressure in patients converted from 0.5% Timolol to Metipranolol.”

Dorzolamide Corneal Safety – Merck 048 (1994)
“A comparison of the corneal safety of 0.2% MK-507 Ophthalmic Solution, 0.5% Timolol Ophthalmic Solution, and 0.5% Betaxolol Solution in patients with elevated intraocular pressure with ocular hypertension or glaucoma.”

Metipranolol/Pilocarpine Combination – Bausch & Lomb 9401 (1994)
“Metipranolol/pilocarpine combination for 12 weeks in ocular hypertension or glaucoma with open angles.”

“The long-term safety and ocular hypotensive efficacy of Brimonidine Tartrate 0.2% in individuals with open-angle glaucoma or ocular hypertension for an extension period of 12 months.”

“A vehicle-controlled study evaluating the ocular safety and efficacy of ketorolac tromethamine 0.5% ophthalmic solution in subjects with inflammation following cataract surgery.”

“The three month safety and ocular hypotensive efficacy of Brimonidine Tartrate 0.2 % vs. Betaxolol 0.25% in subjects with open-angle glaucoma or ocular hypertension.”
Dorzolamide added to Timolol – Merck 053 (1996)
“A study of the effect of adding 2.0% MK-507 opthalmic solution to 0.5% TimopticXE in patient with elevated intraocular pressure.”

Dorzolamide added to Timoptic – Merck 064 (1996)
“A parallel, randomized, double-masked study comparing the 0.5% timolol/2.0% MK-527 combination opthalmic solution b.i.d. to 0.5% timolol ophthalmic solution b.i.d. or 2.0% MK-507 opthalmic solution t.i.d. in patients with elevated intraocular pressure who are inadequately controlled on timolol alone.”

Lotemax – Alcon (1996)
“A comparison of the safety and efficacy of Lotemax and Prednisolone Acetate in acute anterior uveitis.”

Cyclosporin – Allergan 192371-002 (1996)
“A comparison of the safety and efficacy of Cyclosporine 0.05% and 0.1% ophthalmic emulsion in patients with moderate to severe keratoconjunctivitis sicca.”

Brimonidine-ALT - Allergan (1997)
“A comparison of Brimonidine Tartrate 0.02% to Apraclonidine 1.0% for the control of intraocular pressure spikes following argon laser trabeculoplasty.”

Brimonidine PFT – Allergan 190342-002 (1997)
“A study of cardiopulmonary safety of topical Brimonidine Tartrate 0.2% compared with Timolol 0.5% in subjects with glaucoma or ocular hypertension who have been chronically treated with Timolol 0.5%.”

Timolol Spray (1997)
“A study using Timolol 0.05% spray as an alternative delivery system.”

Timolol Gel – Alcon (1997-1998)
“A comparison of Timolol Gel Forming Solution 0.5% and Timoptic XE 0.05% in patients with ocular hypertension or glaucoma.”

Timolol Gum – Merck (1997)
“A study comparing 2.0% Dorzolamide/Xantham Gum to Trusopt in patients with elevated intraocular pressure.”

Hypotensive Lipids – Allergan (1998)
“A comparison of safety and efficacy of AGN 192024 0.03% and AGN 192151 0.06% ophthalmic solutions to vehicle and Latanoprost 0.005% in patients with ocular hypertension or glaucoma.”

Normal Tension Glaucoma (1998)
“A comparison studying the effects of Brimondine 0.2% and Timolol .05% on visual field stability in patients with low pressure glaucoma.”

Memantine Screening – Allergan (1998)
“Screening for a clinical trial of oral memantine in patients with ocular hypertension.”

Unilateral Glaucoma (1998)
“Comparison of brimonidine to timolol in reducing the incidence of glaucomatous damage in unaffected eyes of patients with unilateral glaucoma.”

Brimonidine-Purite – Allergan (1998-1999)
“A multi-center, double-masked, randomized, parallel, one year study of the safety, efficacy, and acceptability of three-times daily dosed 0.2% Brimondine-Purite™ compared with Timoptic inpatients with glaucoma or ocular hypertension.”

“A multi-center, double-masked, parallel, unevenly randomized study of the safety and efficacy of once-daily administered AGN 192024 0.03% ophthalmic solution compared to twice-daily administered timolol 0.5% ophthalmic solution in patients with glaucoma or ocular hypertension.”

Zoptic – KEF 610 (1999)
“A comparative study evaluating equivalence with a clinical endpoint following administration of Zoptic™ or Methazolamide in ocular hypertension or glaucoma.”

“A comparison studying the effects of brimondine 0.2% and timolol 0.5% on visual field stability in patients with low pressure glaucoma.”

Allergan 195024-013 (January 2000-May 2000)
“A comparison of AGN 192024 0.03% with Cosopt BID in patients with glaucoma or ocular hypertension.”

“A comparison of brimonidine vs. latanoprost as first line therapy in glaucoma or ocular hypertension.”

Cosopt vs. Alphagan/Timolol – Merck COS 466 (March 2000-October 2000)
“A comparison of .02% dorzolamide to the concomitant administration of 0.2% brimonidine/0.5% timolol in patients with glaucoma or ocular hypertension.”

Allergan 190342-12T (March 2000-July 2001)
“A comparison of 0.2% brimonidine/0.5% timolol combination with 0.5% timolol or 0.2% brimonidine in patients with glaucoma or ocular hypertension.”
Allergan 192944-005 – Memantine (March 2000-March 2006)  
“A study to evaluate the safety and efficacy of oral memantine in patients with chronic open-angle glaucoma.”

“A comparison of AGN 192024 as alternative therapy adjunctive with 0.5% Timoptic XE and 0.005% Xalatan in patients with glaucoma or ocular hypertension.”

Allergan 190342-017 Brimonidine/Purite (March 2001 – July 2001)  
“A comparison of brimonidine vs. brimondine/purite in patient with glaucoma or ocular hypertension.”

Allergan 192024-019 (March 2001 – December 2001)  
“A comparison of 0.03% AGN 192024 with 0.005% latanoprost in patients with glaucoma or ocular hypertension.”

Allergan 192024-18T (August 2001-August 2003)  
“A comparison of 0.03% bimatorpppost/0.5% timolol combination with 0.5% timolol or 0.03% bimatoprost in patients with glaucoma or ocular hypertension.”

Pharmacia 912-OPT-0076-002 (March 2002-November 2002)  
“A 12 week comparison of the fixed combination of latanoprost and timolol vs. latanoprost vs. timolol in glaucoma patients with optic nerve head abnormalities and visual field defects.’

Alcon C-01-01 (April 2002-October 2006)  
“A 12 week study of the safety and efficacy of Betoptic S 0.25% to Timolol Gel Forming Solution 0.25% and 0.5% in pediatric patients with glaucoma or ocular hypertension.”

Allergan 192024-020 (April 2002-October 2002)  
“A comparison of bimatoprost 0.01% BID, 0.015% BID, 0.02% QD, 0.025% QD with bimotorpost 0.03% and timolol 0.5% BID in patients with glaucoma or ocular hypertension.”

Bimatoprost vs. Latanorpost – Noecker (September 2002 – March 2003)  
“A comparison of bimatoprost 0.03% and latanoprost 0.005% in the treatment of normal tension glaucoma.”

Lipid Add Study - Noecker (November 2002-July 2003)  
“A comparison of brimondine purite 0.15% vs. timolol 0.5% in patients currently using ocular hypotensive lipids for the treatment of glaucoma or ocular hypertension.”

Brimonidine Purite vs. Timolol – Noecker (November 2002-August 2003)
“To compare the IOP-lowering efficacy and quality of life in patients using brimonidine 0.15% or Timolol 0.5% monotherapy for the treatment of glaucoma or ocular hypertension.”

“A comparison of the safety and efficacy of 0.1% brimonidine purite ophthalmic solution dosed three times daily with 0.15% brimonidine purite ophthalmic solution dosed three times daily in patients with glaucoma or ocular hypertension.”

ISTA Pharmaceuticals ISTA-BR-CS001 (July 2003 – December 2003)
“Efficacy and safety of topical bromfenac ophthalmic solution 0.1% vs. placebo for treatment of ocular inflammation following cataract surgery.”

Bimataprost vs. Travoprost – Cantor (September 2003 – January 2005)
“A six month comparison of the safety, efficacy and clinical success of bimatoprost vs. travoprost.”

“Evaluation of bimatoprost 0.03% vs. latanoprost 0.005%: A bilateral monocular trial.”

Inspire Pharmaceuticals 03-109 (April 2004-November 2004)
“A placebo controlled study of multiple ocular instillations of diquasolfof tetrasodium ophthalmic solution, 2% in subjects with dry eye disease.”

Allergan 192024-029 (March 2004-July 2007)
“A masked histological evaluation of trabecular meshwork specimens collected from patients with primary open-angle glaucoma treated with bimatoprost 0.03% ophthalmic solution once daily for at least 2 years compared with primary open-angle glaucoma patients treated with other topical IOP lowering drugs.”

Alcon C-01-78 (May 2004-August 2011)
“A study of the pigmentation in the trabecular meshwork after 2 years of treatment with Travatan 0.004% ophthalmic solution.”

Alcon C-01-79 (May 2004-ongoing)
“A five-year commercial label safety study of Travatan 0.004% induced iris pigmentation study.”

ISTA-VIT-SA-CS06 (October 2004-January 2005)
“Evaluation of Vitrase as an adjuvant to increase the absorption and dispersion of other drugs prior to ocular surgery.”

Brimonidine Purite vs. Dorzolamide-Noecker (October 2004-October 2005)
“A comparison of brimonidine purite 0.15% vs. dorzolamide 2% used as an adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.”
ORA 04-005-02 (October 2004-October 2005)
“A three-month comparison of the efficacy and tolerability of Travatan and Timolol Maleate 0.5% adjunctive therapy vs. Lumigan with Timolol Maleate 0.5% adjunctive therapy in patients with chronic open angle glaucoma or ocular hypertension.”

SLT/MED – Wills/Tulane (January 2005-February 2006)
“A prospective, randomized controlled clinical trial comparing topical medical therapy with Selective Laser Trabeculoplasty (SLT).”

Allergan 192024-030 (January 2005-April 2005)
“A five-day, multi-center, double-masked, randomized paired-eye comparison, active-controlled study of the safety and efficacy of bimatoprost 0.01%, bimatoprost 0.015% with EDTA, bimatoprost 0.015 % and bimatoptost 0.02% once daily compared with Lumigan once-daily in patients with glaucoma or ocular hypertension.”

Allergan Pro2 (January 2005-October 2009)
“An investigator-masked, prospective, randomized, naturalistic, observational study of the safety and efficacy of Lumigan, Xalatan, and Travatan in the management of elevated IOP in patients with open-angle glaucoma or ocular hypertension.”

Allergan 192024-031 (September 2005-August 2007)
“A multi-center, double-masked, randomized, parallel, active-controlled three month study (plus 9 month extension) of the safety and efficacy of bimatoprost ophthalmic solution 0.01% and bimatoprost ophthalmic solution 0.0125% once daily compared with Lumigan 0.03% once daily in patients with glaucoma or ocular hypertension.”

Otsuka 37E-03-202 (December 2005-March 2007)

Alcon C-05-13 (December 2005-July 2006)
“Travatan Dosing Aid.”

ISTA I-06-01 (April 2006-April 2007)
“A single-center, randomized, double-masked patient controlled study to evaluate the comfort of Xibrom compared to Acular LS given concurrently in healthy adult subjects.”

ISTA I-06-02 (April 2006-April 2007)
“A Phase 4, randomized, open-label, patient controlled study to evaluate the efficacy of Xibrom vs. Acular LS for the treatment of ocular inflammation following Selective Laser Trabeculoplasty.”

ISTA-BR-CS02 (June 2006-February 2007)
“Efficacy and Safety of topical bromfenac ophthalmic solution vs. placebo for treatment of ocular inflammation and pain associated with cataract surgery.”

EVOL-PRO-06024 (July 2006-February 2007)
“A multi-center, randomized, double-masked, placebo-controlled, parallel-group study evaluation the safety and efficacy of rEV131 2.5 mg/ml, rEV131 1.25 mg/ml, and rEV131 0.625 mg/ml for the treatment of ocular inflammation after cataract surgery.”

Allergan MA-LUM01 (September 2006-January 2008)
“Evaluation of the IOP lowering effect and tolerability of Lumigan compared with Travatan in patient with glaucoma or ocular hypertension.”

Alcon C-05-31 (January 2007-June 2007)
“A randomized, double-masked safety and efficacy study of FID #109980 compared with FID #110656 in the treatment of dry eye.”

Alcon C-05-03 (July 2007-July 2009)
“Anecortave acetate for steroid-induced IOP elevation.”

Aerie Pharmaceuticals AR-102-CS201 (October 2007-April 2008)
“A phase II fist in human dose-escalation, double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure.”

Allergan 191578-006-00 (November 2007-June 2008)
“A multi-center, double-masked, randomized parallel group study evaluating the safety and efficacy of a new formulation of Ketorolac Tromethamine 0.45% ophthalmic solution compared with vehicle administered pre-operatively and twice-daily post-operatively for two weeks for the treatment of anterior segment inflammation, pain, and inhibition of surgically induced miosis following cataract extraction with Posterior Chamber Intraocular Lens (IOL) Implantation.”

ISTA Pharmaceuticals CL-S&E-0802071-P (January 2008-July 2008)
“Efficacy and safety of Bromfenac Ophthalmic Solution 0.18% QD vs. Xibrom (Bromfenac Ophthalmic Solution) 0.09% QD for the treatment of ocular inflammation, pain, and photophobia associated with cataract surgery.”

Allergan 192024-034-00 (January 2008-December 2008)
“A twelve-week, multi-center, investigator-masked, randomized, parallel-group study to evaluate the safety and efficacy of bimatoprost 0.03% (Lumigan) ophthalmic solution once-daily (QD) compared with latanoprost 0.005% (Xalatan) QD in subjects with glaucoma or ocular hypertension.”

Alcon C-07-36 (June 2008-September 2009)
“A study of the safety and IOP-lowering efficacy of Anecortave Acetate in patients with open-angle glaucoma.”

Alcon C-08-03 (July 2008-August 2009)
“TravatanZ vs. Xalatan in OSDI.”

Alcon C-07-27 (October 2008-September 2009)
“Collection of blood specimens from patients in Anecortave Acetate studies for elevated IOP.”

Inspire 03-113 (January 2009-November 2010)
“A multi-center, parallel-group, double-masked, randomized, placebo-controlled study of the effects of diquasofol tetratosodium ophthalmic solution, 2% in subjects with Dry Eye Disease and a central corneal staining score of 3 (NEI Scale).”

Janix (Allergan) GMA-COM-08-008 (January 2009-January 2010)
“A three-month, investigator-masked, randomized, multi-center, parallel, clinical trial comparing the efficacy of Combigan vs. Xalatan in subjects with ocular hypertension or open-angle glaucoma.”

Aerie Pharmaceuticals AR-12286-CS201 (April 2009-November 2009)
“A phase 2, double-masked, randomized, placebo-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-12286 ophthalmic solution 0.005%, 0.1%, and 0.25% in patients with elevated intraocular pressure.”

Alcon C-08-077 (May 2009-January 2010)
“A randomized, double-masked study of AL-38583 0.05% ophthalmic solution and AL-38583 0.10% ophthalmic solution vs. AL-38583 vehicle in the treatment of dry eye.”

Vistakon Pharmaceuticals CR 1649 (October 2009-March 2010)
“A randomized, double-masked, placebo-controlled, dose-response study of the safety and efficacy of two dosage strengths of the Bimatoprost Punctal Plug Delivery System (BPPDS) compared to placebo, followed by an open-label, single-dose Bimatoprost 0.03% ophthalmic solution (Lumigan) challenge.”

Aerie AR-12286-CS202 (March 2010-September 2010)
“A Phase 2, double-masked, randomized, active-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-12286 in patients with elevated intraocular pressure.

Lilly H6D-MC-LVHQ (April 2010 - ongoing)
“A prospective Case-crossover study to evaluate the possible association between the use of PDE5 inhibitors and the risk of acute nonarteritic anterior ischemic optic neuropathy (NAION).”

Allergan 192024-048 (June 2010 – July 2011)
“A multi-center, double-masked, randomized, parallel study of the safety and efficacy of Bimatoprost 0.03% Preservative-free Ophthalmic Solution compared with Lumigan (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension.”

Alcon C-09-055 (June 2010 – January 2011)
“Clinical evaluation of Nepafenac Ophthalmic Suspension, 0.3% for prevention and treatment of ocular inflammation and pain after cataract surgery.”

Rapid Pathogen Screening Inc. 100310 (December 2010 – July 2011)
“A clinical evaluation of the RPS InflammaDry Detector’s sensitivity and specificity compared to the clinical diagnosis for confirming Dry Eyes.”

Aerie AR-12286-CS203 (January 2011-November 2011)
“A phase 2, Double Masked, Randomized, Active-Controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol added to Patients with Elevated Intraocular Pressure currently using Latanoprost”

Alcon C-10-039 (April 2011-ongoing)
“A Phase III Three-Month, Randomized, Double-Masked, Parallel Group Study with a planned three-month safety extension of the efficacy and safety of a fixed combination of Brinzolamide 1%/Brimonidine 0.2% compared to Brinzolamide 1% and Brimonidine 0.2% all dosed three times daily in patients with Open-Angle glaucoma and/or Ocular Hypertension”

Alcon C-11-034 (November 2011-ongoing)
“A Phase III Multicenter, Double-Masked Study of the Safety and Efficacy of Travaprost Ophthalmic Solution, 0.003% Compared to Travatan in Patients with Open-Angle Glaucoma or Ocular Hypertension”

Sahara 006-00 (March 2011-ongoing)
“A prospective longitudinal observation study to assess the development of ocular surface disease in the treatment-Naïve Glaucoma and Ocular Hypertension patients vs. those without elevated intraocular pressure.”

Monte Dirks, M.D. - Sub-Investigator

Otsuka 37E-03-201 (July 2005-November 2006)

ORA 10-004-01 (Acucela ACU-RED-204) (March 2010 –July 2011)
“A phase II, prospective, randomized, double-masked, parallel group, multi-center study assessing the safety and efficacy of 2% Repabamide (OPC-12759) compared to placebo in
clearing of Fluorescein staining of the central cornea in subjects with Keratoconjunctivitis Sicca (Dry Eye).”

Monte Dirks, M.D. - Unrestricted Grants, Associate Investigator


Ketorolac vs. Prednisolone or Ketorolac/Prednisolone Combination Therapy for Post-Cataract Extraction Cystoid Macular Edema (1998)


Screening for Undetected Optic Nerve Disease in Unilateral Amblyopia (1998-1999)